Cardiac Arrest – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Cardiopulmonary arrest (CPA) refers to the halt of adequate ventilation and circulation, also known as cardiac or circulatory arrest. In adults, it commonly stems from a primary cardiac event. Ventricular fibrillation (VF) accounts for 50 to 80% of cases, with Pulseless electrical activity (PEA) and asystole comprising 20 to 30%. Pulseless sustained ventricular tachycardia (VT) is less frequent but still notable. Without prompt intervention, CPA can lead to sudden death. However, it can be reversed through cardiopulmonary resuscitation (CPR), cardioversion/defibrillation, or cardiac pacing. Early initiation of CPR and cardiac monitoring helps determine the appropriate intervention.
- In the U.S., over 400,000 individuals succumb to CPA annually.
Thelansis’s “Cardiac Arrest Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cardiac Arrest treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Cardiac Arrest across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Cardiac Arrest Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment